Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Xencor has signed an agreement to provide access to one of its Fc engineering patents to Merck, referred to as MSD outside the US and Canada, for a therapeutic monoclonal antibody.
Subscribe to our email newsletter
According to the technology license and option agreement, Merck obtains a non-exclusive license to the patent for use in an undisclosed product in addition to future products.
In exchange, Xencor will earn an upfront payment and annual maintenance fees, while being eligible for milestone payments on successful development of Merck’s product candidates besides sales-based royalties.
Xencor chief executive officer Bassil Dahiyat said, "This technology offers our partners an opportunity to create truly best-in-class therapeutics which will be covered by our ever growing IP portfolio."